As shown in Fig. 4, lower ALDH2 expression in the tumor was also associated with significantly poorer prognosis in BRCA (RFS for 1973 high vs. 1978 low samples, HR = 0.67, CI = 0.6–0.75, p-value = 0; OS for high 701 low vs. 701 low samples, HR = 0.69; CI = 0.56–0.86, p-value = 0.0008) (Fig. 4a and b) and LUAD (time to first progression [FP] for 231 high vs. 230 low samples, HR = 0.4, CI = 0.29–0.56, p-value = 0; OS for 360 high vs. 360 low samples, HR = 0.47, CI = 0.7–0.6, p-value = 0) (Fig. 4c and d). This evidence concerns the gene ALDH2 and neoplasm.